INTRODUCTIONWith nearly 410 000 diagnoses in Europe each year, prostate cancer remains the most commonly diagnosed cancer in men. Approximately 10‐20% of the patients will ultimately advance to lethal, metastatic castration‐resistant prostate cancer (mCRPC). A continued targeting of the androgen receptor (AR) signalling pathway has proven to be useful. This has led to the development and clinical validation of next generation androgen deprivation therapies, encompassing the CYP17 inhibitor abiraterone acetate, and the anti‐androgen enzalutamide. Due to shifts in reimbursement criteria, novel agents and guidelines in the treatment of CRPC, a heterogeneous landscape of patients exists with respect to the current clinical practice. Circulating tumor cell (CTC) enumeration using the CellSearch System demonstrated how CTCs are an accurate and independent predictor of survival in metastatic prostate cancer. Here, we reassessed the prognostic value of baseline CTC enumeration via a prospective, multicentre study in patients with mCRPC starting a new line of systemic therapy with either abiraterone acetate or enzalutamide. Next, we evaluated the association between survival and CTC changes relative to baseline CTC enumeration (ie, CTC dynamics) in patients who responded for at least 10‐12 weeks. Secondary objectives included the assessment of the relationship of CTCs with baseline prostate‐specific antigen (PSA),
The Prostate – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud